Evidence map›Paper›PMID 34621120›Full record

ArticleDrug design, development and therapy2021

The Role of Pretreatment

Jijin Yao, Ying Wang, Yujing Lin, Yingying Yang, Jingjing Wan, Xiaohua Gong, Fanwei Zhang, Wangjian Zhang, Tia Marks, Siyang Wang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Predictive Value of [Journal of clinical medicine · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Jijin Yao *The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.ORCID 0000-0003-4934-4165
Ying Wang *Department of Nuclear Medicine, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.
Yujing LinDepartment of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, 519001, People's Republic of China.
Yingying YangDepartment of Pharmacy, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.
Jingjing WanDepartment of Nuclear Medicine, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.
Xiaohua GongThe Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.
Fanwei ZhangDepartment of Nuclear Medicine, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.
Wangjian ZhangDepartment of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, People's Republic of China.
Tia MarksDepartment of Environmental Health Sciences, School of Public Health, University at Albany, State University of New York, Rensselaer, NY, 12144, USA.
Siyang WangThe Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.
Hongjun JinGuangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.ORCID 0000-0002-1522-1098
Hong ShanGuangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, People's Republic of China.ORCID 0000-0001-6640-1390
Sun Yat-sen University · CNUniversity at Albany, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo evaluate the role of maximal standardized uptake values (SUVmax) and total lesion glycolysis (TLG) from serial

methodsA total of 121 LANPC patients who completed pretreatment

resultsAfter two cycles of NAC, 96 patients were categorized as "responders" and 25 patients as "non-responders". The optimal thresholds of the SUVmax-PT were 11.8 and 38.5 for the TLG-PT. Non-responders were significantly associated with high SUVmax-PT (HR, 3.49; 95% CI, 1.17-10.36;

conclusionPretreatment

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleFluorodeoxyglucose F18GlycolysisHumansMaleMiddle AgedNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoadjuvant TherapyNomogramsPositron Emission Tomography Computed TomographyPrognosisRetrospective StudiesFluorodeoxyglucose F18nasopharyngeal carcinomaneoadjuvant chemotherapynomogramPET/CTtumor response

Identifiers

PMID34621120
PMCPMC8491868
OpenAlexW3201679569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.